Walvax Biotechnology Co.Ltd(300142) ( Walvax Biotechnology Co.Ltd(300142) ) bivalent HPV vaccine has started mass production in early April, and the first batch of products will be on the market soon.
According to media reports, Walvax Biotechnology Co.Ltd(300142) bivalent HPV vaccine has started mass production in early April. At present, about 900000 vaccines in six batches of dynamic verification products are ready for batch issuance. After the batch issuance is qualified, they can take the lead in realizing the listing. As a local enterprise in Yunnan, the company’s bivalent HPV vaccine is expected to achieve the first vaccination in Yunnan.
Previously, the company said at the 2021 annual performance briefing held by panorama that it was expected that the bivalent HPV vaccine could be issued in batches in the second quarter. At present, the company has been carrying out the access work of various provinces and cities in China.
Statistics show that HVP vaccine, as the only vaccine that can prevent cancer in the world, has a wide audience and high awareness. Previously, only Beijing Wantai Biological Pharmacy Enterprise Co.Ltd(603392) ( Beijing Wantai Biological Pharmacy Enterprise Co.Ltd(603392) ) domestic bivalent HPV vaccine was outstanding, and its sales volume has exceeded 10 million doses since it was listed in China. In 2021, a total of 181 batches of HPV vaccines were signed and wholesale in China, with a year-on-year increase of 269%, becoming the largest single product with the fastest volume growth among large varieties of vaccines.
At the end of March this year, Watson bivalent HPV vaccine officially obtained the drug approval. It has the advantages of high safety, flexible vaccination procedures, high standards and high production capacity. The annual production capacity is planned to be 15 million to 30 million doses. Among them, the company said that the whole production plan this year is nearly 10 million doses.
It is understood that the company’s bivalent HPV vaccine is applicable to women aged 9 to 30. The immunization procedure is 3 injections (0, 2 and 6 months), and the vaccination will be completed within 6 months; Women aged 9 to 14 can also use the two needle procedure (0 and 6 months), which can effectively prevent cervical cancer caused by high-risk HPV16 and 18.
The World Health Organization recommends that the age of 9 to 14 is the best age for HPV vaccination. The WHO global strategy for accelerating the elimination of cervical cancer also proposes that by 2030, 90% of girls in the world should complete HPV vaccination before the age of 15, and promote the global goal of eliminating cervical cancer through three-level prevention and control paths such as vaccination, screening and treatment. At present, about 200 countries, including China, have responded. According to industry research, there is a gap of more than 1 billion HPV vaccines in China.
The positive spring breeze of the industry is also reflected in the free vaccination plan. During the two sessions this year, many deputies to the National People’s Congress and members of the CPPCC called for free HPV vaccination for school-age women. According to public information, Xiamen, Jinan, Wuxi, Jiangsu Lianyungang Port Co.Ltd(601008) , Shijiazhuang, Tangshan and other regions have successively launched free vaccination programs of bivalent HPV vaccine. As Zhengzhou, Henan, Shijiazhuang, Hebei, Hainan, Chongqing, Fujian and other places have successively joined the HPV vaccine free vaccination army, the spring of domestic HPV vaccine is coming.
In addition to the HPV vaccine’s normal price in 2021, it is expected that the company will actively promote the work of HPV vaccine in 2021. It is expected that the HPV vaccine will enter the third stage according to the previous work plan.
